my personal edition > colorectal cancer > news
E-Mail this DGDispatch to a colleague
DGDispatch
ERRATUM: Gefitinib (Iressa) Active Against Advanced Colorectal Cancer: Presented at CFS
There was an error in our DG Dispatch (Nov. 12, 2004) based on a presentation at the Chemotherapy Foundation Symposium.
We erroneously reported on the study regimen. Treatment was as follows:
Subjects underwent 14-day treatment cycles. In the first cycle, they received oxaliplatin 85 mg/m2 in a 2-hour intravenous installation on the first day. On the first and second days, they also received leucovorin 200 mg/m2 intravenously, as well as 5-FU 400 mg/m2 in an intravenous push. On those days, patients also received 5-FU 600 mg/m2 for hours 2 to 24. In the second and subsequent cycles, patients received 500 mg of gefitinib orally once daily, along with the combination chemotherapy regimen.
We apologise to the manufacturer for having published inaccurate information on their product.
We are committed to providing the most accurate, relevant and balanced information for physicians worldwide and have devoted considerable resources to ensuring this. We deeply regret this error.
All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.
| 
